Detectable Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following VSV-Ebola Virus Vaccination in Humans

Autor: Poetsch, J, Dahlke, C, Zinser, M, Kasonta, R, Lunemann, S, Rechtien, A, Ly, M, Stubbe, H, Krähling, V, Biedenkopf, N, Eickmann, M, Fehling, S, Olearo, F, Strecker, T, Sharma, P, Lang, K, Lohse, A, Schmiedel, S, Becker, S, Consortium), VEBCON (VSV-Ebola, Addo, M, Bejon, P
Přispěvatelé: Siegrist, Claire-Anne
Rok vydání: 2018
Předmět:
0301 basic medicine
animal diseases
viruses
Medizin
medicine.disease_cause
Ebola virus
vector immunity
0302 clinical medicine
Synthetic/administration & dosage/immunology
vaccine
Immunology and Allergy
030212 general & internal medicine
Vector (molecular biology)
Longitudinal Studies
Ebola Vaccines/administration & dosage/immunology
Vaccines
Immunity
Cellular
Vaccines
Synthetic
ddc:618
biology
3. Good health
Vaccination
Infectious Diseases
Vesicular stomatitis virus
Viruses
VSV-EBOV
preexisting immunity
Antibody
Adult
chemical and pharmacologic phenomena
virus
03 medical and health sciences
Major Articles and Brief Reports
Immune system
Immunity
vesicular stomatitis
medicine
Humans
Ebola Vaccines
Vesiculovirus/immunology
Vesiculovirus
biochemical phenomena
metabolism
and nutrition
biology.organism_classification
Virology
stomatognathic diseases
030104 developmental biology
Immunization
Antibody Formation
biology.protein
bacteria
Cellular
Zdroj: The Journal of Infectious Diseases
The Journal of Infectious Diseases, Vol. 219, No 4 (2019) pp. 556-561
ISSN: 1537-6613
0022-1899
Popis: This study investigates preexisting and vaccine-induced vector immunity in 30 participants of a Phase-1 VSV-EBOV Ebola vaccine trial. No preexisting immunity was detected, however humoral and cell-mediated immunity against internal VSV proteins was observed in up to 36% of vaccines.
In response to the Ebola virus (EBOV) crisis of 2013–2016, a recombinant vesicular stomatitis virus (VSV)–based EBOV vaccine was clinically tested (NCT02283099). A single-dose regimen of VSV-EBOV revealed a safe and immunogenic profile and demonstrated clinical efficacy. While EBOV-specific immune responses to this candidate vaccine have previously been investigated, limited human data on immunity to the VSV vector are available. Within the scope of a phase 1 study, we performed a comprehensive longitudinal analysis of adaptive immune responses to internal VSV proteins following VSV-EBOV immunization. While no preexisting immunity to the vector was observed, more than one-third of subjects developed VSV-specific cytotoxic T-lymphocyte responses and antibodies.
Databáze: OpenAIRE
Externí odkaz: